Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. — PRO-143

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Conjunctivitis, Bacterial Clinical Trial

Official title:
Study to Evaluate the Safety and Tolerability of Pro-143 Ophthalmic Solution in Healthy Volunteers.

Status Withdrawn

Clinical Trial Summary

Study to evaluate the safety and tolerability of PRO-143 solution ophthalmic in healthy volunteers.

A phase I, open label and unicentric clinical trial to evaluate the safety and tolerability of PRO-143 ophthalmic solution in healthy volunteers. ;

See also
Status	Clinical Trial	Phase
Completed	`NCT00407589` - Systemic Pharmacokinetics of BOL-303224-A	Phase 1
Terminated	`NCT03696342` - Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.	Phase 3
Completed	`NCT03987178` - Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists	N/A
Completed	`NCT00357773` - Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis	Phase 3
Completed	`NCT03519516` - Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects	Phase 1
Withdrawn	`NCT01721694` - Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection	Phase 3